PTPN11 and glioblastoma: Notably, phase I clinical trial of TNO155 as the therapeutic agent against solid tumors has already started (https://clinicaltrials.gov/ct2/show/NCT03114319); however, the efficacy of these allosteric inhibitors of SHP2 in GBM treatment has not yet been well-proven.